These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29223348)

  • 1. Distinctive binding properties of the negative allosteric modulator, [
    Fasciani I; Pietrantoni I; Rossi M; Mannoury la Cour C; Aloisi G; Marampon F; Scarselli M; Millan MJ; Maggio R
    Eur J Pharmacol; 2018 Jan; 819():181-189. PubMed ID: 29223348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.
    Silvano E; Millan MJ; Mannoury la Cour C; Han Y; Duan L; Griffin SA; Luedtke RR; Aloisi G; Rossi M; Zazzeroni F; Javitch JA; Maggio R
    Mol Pharmacol; 2010 Nov; 78(5):925-34. PubMed ID: 20702763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The First Negative Allosteric Modulator for Dopamine D
    Rossi M; Fasciani I; Marampon F; Maggio R; Scarselli M
    Mol Pharmacol; 2017 Jun; 91(6):586-594. PubMed ID: 28265019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
    Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
    Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors.
    Cussac D; Newman-Tancredi A; Sezgin L; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):569-72. PubMed ID: 10832613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor.
    Shonberg J; Draper-Joyce C; Mistry SN; Christopoulos A; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2015 Jul; 58(13):5287-307. PubMed ID: 26052807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand.
    Mistry SN; Shonberg J; Draper-Joyce CJ; Klein Herenbrink C; Michino M; Shi L; Christopoulos A; Capuano B; Scammells PJ; Lane JR
    J Med Chem; 2015 Sep; 58(17):6819-43. PubMed ID: 26258690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
    Wood M; Ates A; Andre VM; Michel A; Barnaby R; Gillard M
    Mol Pharmacol; 2016 Feb; 89(2):303-12. PubMed ID: 26655303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysbindin-1 modifies signaling and cellular localization of recombinant, human D₃ and D₂ receptors.
    Schmieg N; Rocchi C; Romeo S; Maggio R; Millan MJ; Mannoury la Cour C
    J Neurochem; 2016 Mar; 136(5):1037-51. PubMed ID: 26685100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
    Coldwell MC; Boyfield I; Brown T; Hagan JJ; Middlemiss DN
    Br J Pharmacol; 1999 Aug; 127(7):1696-702. PubMed ID: 10455328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The action of a negative allosteric modulator at the dopamine D
    Draper-Joyce CJ; Verma RK; Michino M; Shonberg J; Kopinathan A; Klein Herenbrink C; Scammells PJ; Capuano B; Abramyan AM; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Sci Rep; 2018 Jan; 8(1):1208. PubMed ID: 29352161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D2 dopamine receptors and modulation of spontaneous acetylcholine (ACh) release from rat striatal synaptosomes.
    Clos MV; García-Sanz A; Vivas NM; Badia A
    Br J Pharmacol; 1997 Sep; 122(2):286-90. PubMed ID: 9313937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
    Maggio R; Scarselli M; Novi F; Millan MJ; Corsini GU
    J Neurochem; 2003 Nov; 87(3):631-41. PubMed ID: 14535946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for Two Modes of Binding of the Negative Allosteric Modulator SB269,652 to the Dopamine D
    Ågren R; Sahlholm K
    Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D
    Draper-Joyce CJ; Michino M; Verma RK; Klein Herenbrink C; Shonberg J; Kopinathan A; Scammells PJ; Capuano B; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Biochem Pharmacol; 2018 Feb; 148():315-328. PubMed ID: 29325769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D
    Kumar V; Moritz AE; Keck TM; Bonifazi A; Ellenberger MP; Sibley CD; Free RB; Shi L; Lane JR; Sibley DR; Newman AH
    J Med Chem; 2017 Feb; 60(4):1478-1494. PubMed ID: 28186762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.